sumatriptan succinate

FDA Drug Profile — Sumatriptan Succinate, sumatriptan succinate, SUMATRIPTAN SUCCINATE, Onzetra Xsail

sumatriptan succinate is listed in the FDA National Drug Code directory with 36 NDC codes, marketed under brand names including Sumatriptan Succinate, sumatriptan succinate, SUMATRIPTAN SUCCINATE. Available dosage forms: tablet, film coated, injection, capsule.

Drug details

Generic Name
sumatriptan succinate
Brand Names
Sumatriptan Succinate, sumatriptan succinate, SUMATRIPTAN SUCCINATE, Onzetra Xsail
Application Number
ANDA077744
Sponsor
Golden State Medical Supply, Inc.
NDC Codes
36
Dosage Forms
TABLET, FILM COATED, INJECTION, CAPSULE
Routes
ORAL, SUBCUTANEOUS, NASAL
Active Ingredients
SUMATRIPTAN SUCCINATE

Indications and Usage

1 INDICATIONS AND USAGE Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan tablets, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • Sumatriptan tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of sumatriptan tablets have not been established for cluster headache. Sumatriptan tablets are a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. ( 1 ) • Not indicated for the prophylactic therapy of migraine attacks. ( 1 ) • Not indicated for the treatment of cluster headache. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.